The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Studying mutations in the BTK gene in patients with CLL receiving BTK inhibitors
Jennifer Woyach, MD, The Ohio State University, Columbus, OH, comments on a retrospective study using a large genomic database to study the prevalence of BTK mutations in patients with chronic lymphocytic leukemia (CLL) receiving BTK inhibitor therapy. Dr Woyach notes that leveraging these large databases can allow for a better understanding of BTK mutational patterns in groups of patients. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
In a large collaboration with multicenter studies as well as AstraZeneca, we used the NeoGenomics database to look at patients with CLL who had had genetic testing sent and to see whether they had mutations in BTK when they were taking a BTK inhibitor. Of course, this is a very unselected patient population, but just interested to see when looking at very large numbers of patients who are presumably mostly still in remission, whether we see evidence of BTK mutations...
In a large collaboration with multicenter studies as well as AstraZeneca, we used the NeoGenomics database to look at patients with CLL who had had genetic testing sent and to see whether they had mutations in BTK when they were taking a BTK inhibitor. Of course, this is a very unselected patient population, but just interested to see when looking at very large numbers of patients who are presumably mostly still in remission, whether we see evidence of BTK mutations. We were able to see over 13,000, actually almost 14,000 patients. Primarily, these patients were on BTK inhibitors in the frontline setting. We did see a very low rate of BTK mutations at 1.7% in total. And we saw a few different types of BTK mutations with C41S being the most common. I think this is really exciting data because it tells us that we can leverage these large databases to understand better who is getting mutations and when people are getting mutations and we’re excited to take this further in the future to try to get more granularity on these data.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
AstraZeneca: Consultancy; Newave: Consultancy; Genentech, Inc.: Consultancy; Janssen: Research Funding; Loxo Lilly: Consultancy; BeiGene: Consultancy; AbbVie: Research Funding; Merck: Consultancy; Pharmacyclics: Consultancy, Research Funding; Schrodinger: Research Funding; Morphosys: Research Funding.
